Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the ...
Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to 2 years old, in a phase 2 study.
Please provide your email address to receive an email when new articles are posted on . Infants diagnosed with atopic dermatitis are more likely to develop asthma, allergic rhinitis and food allergies ...
As the 2026 American Academy of Dermatology (AAD) annual meeting approaches, MedPage Today is offering a preview of an ...
Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints: Indianapolis Tuesday, ...
Newborns who go on to develop atopic dermatitis (AD) show higher transepidermal water loss (TEWL) and cord blood serum levels of CCL17/thymus- and activation-regulated chemokine (TARC) and interleukin ...
Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.
Most people with atopic dermatitis (a type of eczema) are able to control their symptoms by using topical treatments that are applied to the skin. But for some people with severe atopic dermatitis, ...
Home based, tailored intervention to reduce rate of falls after stroke (FAST): randomised trial 1. The tailored, multidisciplinary home‑based program significantly reduced the rate of falls after ...
If you’re struggling with dry skin this winter, we know it can feel like an uphill battle to keep your skin moisturized. Throw dermatitis into the mix, and the frustration compounds. No one wants to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results